Lipitor (Atorvastatin Calcium) Products Liability Litigation
MDL No. 2502

Introduction


This multidistrict litigation currently consists of over two thousand cases pending before this Court, and additional cases are expected to be filed or transferred to this Court in the coming months. These cases all involve allegations concerning the medication Lipitor (Atorvastatin Calcium). Lipitor is commonly prescribed to aid in lowering cholesterol and triglycerides. The plaintiffs allege that Lipitor caused them to develop type 2 diabetes and related injuries. Pfizer denies these claims.

The Judicial Panel on Multidistrict Litigation determined that the Lipitor cases filed involved common questions of fact and that centralization of the Lipitor cases was appropriate. Weighing a number of factors, the Judicial Panel selected the District of South Carolina as the forum for this litigation. These cases have been assigned to the Honorable Richard M. Gergel for coordinated discovery and pretrial matters.

On January 25, 2016, the Court ordered all Plaintiffs to show cause why their claims could survive summary judgment, given the Court’s orders regarding expert testimony on causation in two bellwether cases. No Plaintiff came forward, and the Court granted summary judgment in all cases pending as of January 25, 2016. The only cases remaining in this multidistrict litigation are cases that became part of it after the Court’s January 25, 2016 order to show cause. On January 3, 2017, the Court ordered all remaining Plaintiffs to show cause why the Court should not grant summary judgment to Defendant(s). That order also applies to any new action docketed in this multidistrict litigation on or after January 3, 2017. As of January 4, 2017, the Judicial Panel on Multidistrict Litigation has ceased to transfer and consolidate new cases to this multidistrict litigation.